Viewing Study NCT06095089



Ignite Creation Date: 2024-05-06 @ 7:41 PM
Last Modification Date: 2024-10-26 @ 3:11 PM
Study NCT ID: NCT06095089
Status: RECRUITING
Last Update Posted: 2024-06-20
First Post: 2023-10-18

Brief Title: A Study of JNJ-87189401 Plus JNJ-78278343 for Advanced Prostate Cancer
Sponsor: Janssen Research Development LLC
Organization: Janssen Research Development LLC

Study Overview

Official Title: A Phase 1 Study of JNJ-87189401 PSMA-CD28 Bispecific Antibody Combined With JNJ-78278343 KLK2-CD3 Bispecific Antibody for Advanced Prostate Cancer
Status: RECRUITING
Status Verified Date: 2024-10
Last Known Status: None
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: None
Brief Summary: The purpose of the study is to determine the recommended regimen for Phase 2 RP2Rs of combination of JNJ-87189401 with JNJ-78278343 Part 1 dose escalation and further evaluate the safety at RP2Rs Part 2 dose expansion in participants with advanced prostate cancer
Detailed Description: None

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: True
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: True
Is an FDA AA801 Violation?: None
Secondary IDs
Secondary ID Type Domain Link
87189401PCR1001 OTHER None None
2023-504063-17-00 REGISTRY EUCT number None